Benzinga · Oct 9, 2026
UBS Maintains Buy on Biogen, Raises Price Target to $270
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.
NASDAQ · BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
$225.71
Up+$7.28 (+3.33%)
Updated Oct 12, 2026, 2:45 AM
SID Score
6.7/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 25.33B
- P/E ratio
- 15.74
- Dividend yield
- 0.00%
- 52-week range
- $160.36 – $230.49
- Volume
- 815.01K
- Avg. volume
- 1.8M
Price performance · BIIB
BIIB price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
BIIB closed at $225.71 after 20 trading sessions, up 3.84% for the selected period.
- Last close
- $225.71
- Period change
- +3.84%
- Period low
- $215.50
- Period high
- $228.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $220.62 | $227.20 | $219.225 | $225.71 | 815.01K |
| Oct 8, 2026 | $220.15 | $223.085 | $215.73 | $218.43 | 1.34M |
| Oct 7, 2026 | $222.93 | $228.00 | $221.40 | $222.15 | 1.3M |
| Oct 6, 2026 | $224.53 | $225.97 | $218.00 | $222.89 | 1.01M |
| Oct 5, 2026 | $219.90 | $223.85 | $218.22 | $223.59 | 951.32K |
| Oct 2, 2026 | $222.98 | $224.08 | $219.81 | $219.88 | 780.43K |
| Oct 1, 2026 | $225.50 | $228.31 | $222.50 | $222.82 | 1.76M |
| Sep 30, 2026 | $227.23 | $229.36 | $225.505 | $225.88 | 1.55M |
| Sep 29, 2026 | $227.02 | $229.41 | $224.45 | $227.07 | 1.16M |
| Sep 28, 2026 | $225.87 | $230.49 | $225.51 | $228.69 | 1.33M |
| Sep 25, 2026 | $228.27 | $228.92 | $223.76 | $227.60 | 958.03K |
| Sep 24, 2026 | $226.80 | $228.72 | $224.305 | $226.36 | 1.03M |
| Sep 23, 2026 | $226.94 | $229.19 | $222.355 | $227.53 | 1.49M |
| Sep 22, 2026 | $219.22 | $226.43 | $219.00 | $225.36 | 1.11M |
| Sep 21, 2026 | $216.14 | $221.92 | $214.59 | $219.07 | 928.56K |
| Sep 18, 2026 | $219.05 | $220.17 | $215.26 | $215.50 | 2.64M |
| Sep 17, 2026 | $217.68 | $219.41 | $215.33 | $219.05 | 836.71K |
| Sep 16, 2026 | $216.41 | $218.29 | $214.81 | $216.01 | 606.49K |
| Sep 15, 2026 | $216.71 | $216.71 | $213.54 | $216.17 | 756.05K |
| Sep 14, 2026 | $221.00 | $222.245 | $215.56 | $217.36 | 629.93K |
Latest BIIB news
The latest Smart Investors Daily articles mentioning BIIB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BIIB research
Overview
Company profile and research snapshot.
Company profile
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $177.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | UBS | Buy | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 10, 2026 | HSBC | Reduce | — |
| Sep 3, 2026 | Piper Sandler | Overweight | — |
| Aug 25, 2026 | RBC Capital | Outperform | — |
News briefing
Generated Oct 11, 2026, 9:10 PM
Why Is BIIB Up Today?
Biogen shares gained 3.33% today, climbing $7.28 as UBS reiterated its confidence in the biotech company with a maintained Buy rating and an elevated price target. The analyst upgrade signals continued optimism about Biogen's pipeline and commercial prospects, providing a tailwind for the stock in an otherwise volatile biotech sector.
Bottom line: Biogen's 3.33% gain reflects renewed analyst support from UBS with an attractive $270 price target, signaling institutional confidence in the company's value proposition. Investors should monitor upcoming pipeline catalysts and commercial execution while remaining mindful of competitive headwinds and the broader biotech market environment that could influence near-term volatility.
Benzinga · Oct 8, 2026
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.
Yahoo · Oct 6, 2026
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development...
Yahoo · Oct 6, 2026
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
